Zuo Z, Meng Q, Cui J, Guo K, Bian H
Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(5):920-929.
PMID: 38862450
PMC: 11166723.
DOI: 10.12122/j.issn.1673-4254.2024.05.14.
Hitraya E, Gaidarova S, Piera-Velazquez S, Jimenez S
Connect Tissue Res. 2024; 65(2):161-169.
PMID: 38436275
PMC: 10994737.
DOI: 10.1080/03008207.2024.2319051.
Yang H, Cheong S, He Y, Lu F
Stem Cell Res Ther. 2023; 14(1):372.
PMID: 38111001
PMC: 10729330.
DOI: 10.1186/s13287-023-03543-w.
Piera-Velazquez S, Jimenez S
J Clin Med. 2021; 10(20).
PMID: 34682914
PMC: 8539594.
DOI: 10.3390/jcm10204791.
Abignano G, Hermes H, Piera-Velazquez S, Addya S, Del Galdo F, Jimenez S
Sci Rep. 2021; 11(1):20435.
PMID: 34650102
PMC: 8516909.
DOI: 10.1038/s41598-021-99292-y.
Selective deletion of connective tissue growth factor attenuates experimentally-induced pulmonary fibrosis and pulmonary arterial hypertension.
Tam A, Horwell A, Trinder S, Khan K, Xu S, Ong V
Int J Biochem Cell Biol. 2021; 134:105961.
PMID: 33662577
PMC: 8111417.
DOI: 10.1016/j.biocel.2021.105961.
Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update.
Utsunomiya A, Oyama N, Hasegawa M
J Clin Med. 2020; 9(11).
PMID: 33105647
PMC: 7690387.
DOI: 10.3390/jcm9113388.
Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?.
Frohlich J, Vinciguerra M
Geroscience. 2020; 42(6):1475-1498.
PMID: 33025411
PMC: 7732895.
DOI: 10.1007/s11357-020-00279-w.
Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.
Bonhomme O, Andre B, Gester F, de Seny D, Moermans C, Struman I
Rheumatology (Oxford). 2019; 58(9):1534-1546.
PMID: 31292645
PMC: 6736409.
DOI: 10.1093/rheumatology/kez230.
Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases.
Piera-Velazquez S, Jimenez S
Physiol Rev. 2019; 99(2):1281-1324.
PMID: 30864875
PMC: 6734087.
DOI: 10.1152/physrev.00021.2018.
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy.
Di Benedetto P, Liakouli V, Ruscitti P, Berardicurti O, Carubbi F, Panzera N
Arthritis Res Ther. 2018; 20(1):223.
PMID: 30285896
PMC: 6235209.
DOI: 10.1186/s13075-018-1719-4.
Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
Wermuth P, Jimenez S
PLoS One. 2018; 13(5):e0196559.
PMID: 29718973
PMC: 5931634.
DOI: 10.1371/journal.pone.0196559.
Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives.
Mendoza F, Mansoor M, Jimenez S
Expert Opin Orphan Drugs. 2016; 4(1):31-47.
PMID: 27812432
PMC: 5087809.
DOI: 10.1517/21678707.2016.1114454.
Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases.
Piera-Velazquez S, Mendoza F, Jimenez S
J Clin Med. 2016; 5(4).
PMID: 27077889
PMC: 4850468.
DOI: 10.3390/jcm5040045.
Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?.
Jimenez S, Piera-Velazquez S
Matrix Biol. 2016; 51:26-36.
PMID: 26807760
PMC: 4842122.
DOI: 10.1016/j.matbio.2016.01.012.
Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.
Piera-Velazquez S, Makul A, Jimenez S
Arthritis Rheumatol. 2015; 67(10):2749-58.
PMID: 26096997
PMC: 4581953.
DOI: 10.1002/art.39242.
Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis.
Jimenez S
ISRN Rheumatol. 2013; 2013:835948.
PMID: 24175099
PMC: 3794556.
DOI: 10.1155/2013/835948.